ID   RenCares
AC   CVCL_YT60
DR   Wikidata; Q98128902
RX   PubMed=31031856;
CC   Selected for resistance to: ChEBI; CHEBI:68478; Everolimus (RAD001).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
CC   Breed/subspecies: BALB/c.
DI   NCIt; C124802; Mouse kidney carcinoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2174 ! RenCa
SX   Male
AG   6W
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 29-06-23; Version: 4
//
RX   PubMed=31031856; DOI=10.7150/jca.29192;
RA   Nayman A.H., Siginc H., Zemheri E., Yencilek F., Yildirim A.,
RA   Telci D.;
RT   "Dual-inhibition of mTOR and Bcl-2 enhances the anti-tumor effect of
RT   everolimus against renal cell carcinoma in vitro and in vivo.";
RL   J. Cancer 10:1466-1478(2019).
//